Arcturus Therapeutics (ARCT) COVID Vaccine News 'Encouraging' - Laidlaw
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Arcturus Therapeutics (ARCT) Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 16, 2021 8:01 AM ESTArcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern
ARCT-154 and ARCT-165 are being studied in a Phase 1/2 trial, sponsored by Arcturus, in U.S. and Singapore. The study is evaluating Arcturus COVID vaccine candidates as both a primary vaccination series and as a booster following initial... More
